Navigation Links
Trovagene to Present at Two Healthcare Conferences
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2013 healthcare conferences: Rodman & Renshaw and Stifel.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Rodman & Renshaw 15th Annual Global Healthcare ConferenceTrovagene is scheduled to present at the 15th Annual Rodman & Renshaw Global Healthcare Conference at the Millennium Broadway Hotel in New York, NY on Monday, September 9, 2013 at 3:15 p.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://www.wsw.com/webcast/rrshq23/TROV and can also be accessed through the investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.

Stifel Healthcare Conference 2013Trovagene is scheduled to present at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA on Wednesday, September 11, 2013 at 10:20 a.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://www.veracast.com/webcasts/stifel/healthcare2013/92105578306.cfm and can also be accessed through the investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.

About Trovagene, Inc.Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

Chief Financial OfficerAmy Caterina

Investor RelationsTrovagene, Inc.Trovagene, Inc.858-952-7594858-952-7593szaniboni@trovagene.comacaterina@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trovagene to Present at Leerink Swan Global Healthcare Conference
2. Trovagene to be Added to Russell Microcap Index
3. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
4. Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
5. TrovaGene Acquires CLIA - Certified Laboratory
6. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
7. Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
8. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. ANP to present at and attend major US investment, partnering and industry conferences
10. Cambridge Semantics to Present on ‘Smart Data’ During Deep-Dive Workshop at 2013 Big Data Innovation Summit
11. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  As a ... Abuse and Heroin Summit ,  Proove® Biosciences, Inc. ... analyzing genetics, environmental, and lifestyle factors to accurately ... the University of Southern California (USC), the Interventional ... and Proove publish results showing that Proove Opioid ...
(Date:4/19/2017)... FRANCISCO, Calif. , April 19, 2017 /PRNewswire/ ... VCYT ) today announced that it will report ... of market on Wednesday, May 3, 2017. Following the ... webcast at 4:30 p.m. Eastern Time to discuss the company,s ... live webcast and subsequent replay may be accessed ...
(Date:4/18/2017)... ... April 18, 2017 , ... ... converts conductivity readings to concentration levels and vice-versa. , One of the key ... solution strength in concentration control or monitoring. The principle of this analytical method ...
(Date:4/18/2017)... Austin, Texas (PRWEB) , ... April 18, 2017 , ... ... Miami Research Associates, co-members in the VaxCorps vaccine consortium, were named one of the ... top finalist since the inception of this category; winning the award four times previously, ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):